Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants

Eli D. Ehrenpreis, Humberto Sifuentes, Jamie E. Ehrenpreis, Zachary L. Smith, Mike L. Marshall

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: The Adverse Events Reporting System (AERS) of the FDA is used to identify toxicities of drugs that are on the market. Nurse practitioners (NP) and physician assistants (PA), having an increasing role in the delivery of medical care, are also needed to participate in post-marketing pharmacovigilance. This study was performed to assess awareness and use of the AERS in voluntary reporting of drug toxicities by NPs and PAs. Methods: A cluster sample survey was issued at the Principles of Gastroenterology for the Nurse Practitioner and Physician Assistant course in August 2010. The survey assessed familiarity with the AERS, the number of adverse events seen and the frequency of reports sent to the AERS. NP and PA responses were compared using the two-tailed Fisher's exact. Results: Of the 92 respondents, 67 (72%) were NPs and 24 (26%) PAs. Of the 50 (54%) respondents that reported being familiar with the AERS system, 20 (40%) incorrectly identified the methods to report using the AERS. Overall reporting of adverse events was low, particularly in respondents seeing 512 adverse events per year. Conclusion: The study suggests that improved education regarding the importance of using AERS for pharmacovigilance is suggested for NPs and PAs. Due to the small size of the study, these data should be viewed as preliminary, pending a larger confirmatory study.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalExpert Opinion on Drug Safety
Volume11
Issue number2
DOIs
StatePublished - Mar 1 2012

Fingerprint

Physician Assistants
Nurse Practitioners
Pharmacovigilance
Drug-Related Side Effects and Adverse Reactions
Gastroenterology
Marketing
Surveys and Questionnaires
Education

Keywords

  • Adverse drug reactions
  • Adverse events reporting system
  • FDA
  • Nurse practitioners
  • Pharmacology
  • Pharmacovigilence
  • Physician assistants
  • Side effects

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants. / Ehrenpreis, Eli D.; Sifuentes, Humberto; Ehrenpreis, Jamie E.; Smith, Zachary L.; Marshall, Mike L.

In: Expert Opinion on Drug Safety, Vol. 11, No. 2, 01.03.2012, p. 177-183.

Research output: Contribution to journalArticle

Ehrenpreis, Eli D. ; Sifuentes, Humberto ; Ehrenpreis, Jamie E. ; Smith, Zachary L. ; Marshall, Mike L. / Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants. In: Expert Opinion on Drug Safety. 2012 ; Vol. 11, No. 2. pp. 177-183.
@article{7a22c538203c42eaa66362461db59f15,
title = "Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants",
abstract = "Objectives: The Adverse Events Reporting System (AERS) of the FDA is used to identify toxicities of drugs that are on the market. Nurse practitioners (NP) and physician assistants (PA), having an increasing role in the delivery of medical care, are also needed to participate in post-marketing pharmacovigilance. This study was performed to assess awareness and use of the AERS in voluntary reporting of drug toxicities by NPs and PAs. Methods: A cluster sample survey was issued at the Principles of Gastroenterology for the Nurse Practitioner and Physician Assistant course in August 2010. The survey assessed familiarity with the AERS, the number of adverse events seen and the frequency of reports sent to the AERS. NP and PA responses were compared using the two-tailed Fisher's exact. Results: Of the 92 respondents, 67 (72{\%}) were NPs and 24 (26{\%}) PAs. Of the 50 (54{\%}) respondents that reported being familiar with the AERS system, 20 (40{\%}) incorrectly identified the methods to report using the AERS. Overall reporting of adverse events was low, particularly in respondents seeing 512 adverse events per year. Conclusion: The study suggests that improved education regarding the importance of using AERS for pharmacovigilance is suggested for NPs and PAs. Due to the small size of the study, these data should be viewed as preliminary, pending a larger confirmatory study.",
keywords = "Adverse drug reactions, Adverse events reporting system, FDA, Nurse practitioners, Pharmacology, Pharmacovigilence, Physician assistants, Side effects",
author = "Ehrenpreis, {Eli D.} and Humberto Sifuentes and Ehrenpreis, {Jamie E.} and Smith, {Zachary L.} and Marshall, {Mike L.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1517/14740338.2012.650165",
language = "English (US)",
volume = "11",
pages = "177--183",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants

AU - Ehrenpreis, Eli D.

AU - Sifuentes, Humberto

AU - Ehrenpreis, Jamie E.

AU - Smith, Zachary L.

AU - Marshall, Mike L.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Objectives: The Adverse Events Reporting System (AERS) of the FDA is used to identify toxicities of drugs that are on the market. Nurse practitioners (NP) and physician assistants (PA), having an increasing role in the delivery of medical care, are also needed to participate in post-marketing pharmacovigilance. This study was performed to assess awareness and use of the AERS in voluntary reporting of drug toxicities by NPs and PAs. Methods: A cluster sample survey was issued at the Principles of Gastroenterology for the Nurse Practitioner and Physician Assistant course in August 2010. The survey assessed familiarity with the AERS, the number of adverse events seen and the frequency of reports sent to the AERS. NP and PA responses were compared using the two-tailed Fisher's exact. Results: Of the 92 respondents, 67 (72%) were NPs and 24 (26%) PAs. Of the 50 (54%) respondents that reported being familiar with the AERS system, 20 (40%) incorrectly identified the methods to report using the AERS. Overall reporting of adverse events was low, particularly in respondents seeing 512 adverse events per year. Conclusion: The study suggests that improved education regarding the importance of using AERS for pharmacovigilance is suggested for NPs and PAs. Due to the small size of the study, these data should be viewed as preliminary, pending a larger confirmatory study.

AB - Objectives: The Adverse Events Reporting System (AERS) of the FDA is used to identify toxicities of drugs that are on the market. Nurse practitioners (NP) and physician assistants (PA), having an increasing role in the delivery of medical care, are also needed to participate in post-marketing pharmacovigilance. This study was performed to assess awareness and use of the AERS in voluntary reporting of drug toxicities by NPs and PAs. Methods: A cluster sample survey was issued at the Principles of Gastroenterology for the Nurse Practitioner and Physician Assistant course in August 2010. The survey assessed familiarity with the AERS, the number of adverse events seen and the frequency of reports sent to the AERS. NP and PA responses were compared using the two-tailed Fisher's exact. Results: Of the 92 respondents, 67 (72%) were NPs and 24 (26%) PAs. Of the 50 (54%) respondents that reported being familiar with the AERS system, 20 (40%) incorrectly identified the methods to report using the AERS. Overall reporting of adverse events was low, particularly in respondents seeing 512 adverse events per year. Conclusion: The study suggests that improved education regarding the importance of using AERS for pharmacovigilance is suggested for NPs and PAs. Due to the small size of the study, these data should be viewed as preliminary, pending a larger confirmatory study.

KW - Adverse drug reactions

KW - Adverse events reporting system

KW - FDA

KW - Nurse practitioners

KW - Pharmacology

KW - Pharmacovigilence

KW - Physician assistants

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84857387094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857387094&partnerID=8YFLogxK

U2 - 10.1517/14740338.2012.650165

DO - 10.1517/14740338.2012.650165

M3 - Article

C2 - 22316142

AN - SCOPUS:84857387094

VL - 11

SP - 177

EP - 183

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 2

ER -